These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 28286977)

  • 101. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.
    Portal A; Pernot S; Tougeron D; Arbaud C; Bidault AT; de la Fouchardière C; Hammel P; Lecomte T; Dréanic J; Coriat R; Bachet JB; Dubreuil O; Marthey L; Dahan L; Tchoundjeu B; Locher C; Lepère C; Bonnetain F; Taieb J
    Br J Cancer; 2015 Sep; 113(7):989-95. PubMed ID: 26372701
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX.
    Peixoto RD; Ho M; Renouf DJ; Lim HJ; Gill S; Ruan JY; Cheung WY
    Am J Clin Oncol; 2017 Oct; 40(5):507-511. PubMed ID: 25844823
    [TBL] [Abstract][Full Text] [Related]  

  • 103. A real-world analysis of second-line treatment option, gemcitabine plus anlotinib and anti-PD1, in advanced pancreatic cancer.
    Fan M; Ma Y; Deng G; Si H; Jia R; Wang Z; Dai G
    Pancreatology; 2024 Jun; 24(4):579-583. PubMed ID: 38553260
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
    Lee K; Bang K; Yoo C; Hwang I; Jeong JH; Chang HM; Oh D; Song TJ; Park DH; Lee SS; Lee SK; Kim MH; Park JH; Kim KP; Ryoo BY
    Cancer Res Treat; 2020 Jan; 52(1):254-262. PubMed ID: 31291709
    [TBL] [Abstract][Full Text] [Related]  

  • 105. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
    Assaf E; Verlinde-Carvalho M; Delbaldo C; Grenier J; Sellam Z; Pouessel D; Bouaita L; Baumgaertner I; Sobhani I; Tayar C; Paul M; Culine S
    Oncology; 2011; 80(5-6):301-6. PubMed ID: 21778770
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer.
    Ueno H; Ikeda M; Ueno M; Mizuno N; Ioka T; Omuro Y; Nakajima TE; Furuse J
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):595-603. PubMed ID: 26842789
    [TBL] [Abstract][Full Text] [Related]  

  • 107. ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?
    Ushida Y; Inoue Y; Oba A; Mie T; Ito H; Ono Y; Sato T; Ozaka M; Sasaki T; Saiura A; Sasahira N; Takahashi Y
    Ann Surg Oncol; 2022 Aug; 29(8):5051-5052. PubMed ID: 35366705
    [No Abstract]   [Full Text] [Related]  

  • 108. Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel
    Taguchi H; Otsuka T; Shimokawa M; Arima S; Hashimoto S; Ido A; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Fukahori M; Makiyama A; Honda T; Shibuki T; Mizuta T; Mitsugi K; Nio K; Ide Y; Ureshino N; Shirakawa T
    Anticancer Res; 2021 Jul; 41(7):3573-3582. PubMed ID: 34230153
    [TBL] [Abstract][Full Text] [Related]  

  • 109. An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel.
    Youn S; Chen A; Ha V; Chambers C; Eurich DT; McCall M; Sawyer MB
    Clin Nutr; 2021 Aug; 40(8):4888-4892. PubMed ID: 34358833
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
    Orlandi A; Calegari MA; Martini M; Cocomazzi A; Bagalà C; Indellicati G; Zurlo V; Basso M; Cassano A; Larocca LM; Barone C
    Clin Transl Oncol; 2016 Oct; 18(10):988-95. PubMed ID: 26742940
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
    Sams L; Kruger S; Heinemann V; Bararia D; Haebe S; Alig S; Haas M; Zhang D; Westphalen CB; Ormanns S; Metzger P; Werner J; Weigert O; von Bergwelt-Baildon M; Rataj F; Kobold S; Boeck S
    Clin Transl Oncol; 2021 Nov; 23(11):2394-2401. PubMed ID: 33876417
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Treatment landscape of metastatic pancreatic cancer.
    De Dosso S; Siebenhüner AR; Winder T; Meisel A; Fritsch R; Astaras C; Szturz P; Borner M
    Cancer Treat Rev; 2021 May; 96():102180. PubMed ID: 33812339
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Optimizing initial chemotherapy for metastatic pancreatic cancer.
    Mantripragada KC; Safran H
    Future Oncol; 2016 May; 12(9):1125-33. PubMed ID: 26939741
    [TBL] [Abstract][Full Text] [Related]  

  • 115. nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial.
    Young R; Mainwaring P; Clingan P; Parnis FX; Asghari G; Beale P; Aly A; Botteman M; Romano A; Ferrara S; Margunato-Debay S; Harris M
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e325-e331. PubMed ID: 29932294
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort.
    Walma MS; Brada LJ; Patuleia SIS; Blomjous JG; Bollen TL; Bosscha K; Bruijnen RC; Busch OR; Creemers GJ; Daams F; van Dam R; Festen S; Jan de Groot D; Willem de Groot J; Mohammad NH; Hermans JJ; de Hingh IH; Kerver ED; van Leeuwen MS; van der Leij C; Liem MS; van Lienden KP; Los M; de Meijer VE; Meijerink MR; Mekenkamp LJ; Nederend J; Nio CY; Patijn GA; Polée MB; Pruijt JF; Renken NS; Rombouts SJ; Schouten TJ; Stommel MWJ; Verweij ME; de Vos-Geelen J; de Vries JJJ; Vulink A; Wessels FJ; Wilmink JW; van Santvoort HC; Besselink MG; Molenaar IQ;
    Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):699-707. PubMed ID: 33280952
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer.
    Kokkali S; Tripodaki ES; Drizou M; Stefanou D; Magou E; Zylis D; Kapiris M; Nasi D; Georganta C; Ardavanis A
    In Vivo; 2018; 32(3):653-657. PubMed ID: 29695574
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.
    Vreeland TJ; McAllister F; Javadi S; Prakash LR; Fogelman DR; Ho L; Varadhachary G; Aloia TA; Vauthey JN; Lee JE; Kim MP; Katz MHG; Tzeng CD
    Pancreas; 2019 Jul; 48(6):837-843. PubMed ID: 31210666
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial.
    Assenat E; de la Fouchardière C; Portales F; Ychou M; Debourdeau A; Desseigne F; Iltache S; Fiess C; Mollevi C; Mazard T
    ESMO Open; 2021 Dec; 6(6):100318. PubMed ID: 34837745
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Efficacy and safety of neoadjuvant Folfirinox and Gemcitabine plus Nab-Paclitaxel for borderline resectable and locally advanced pancreatic cancer: a systematic review and meta-analysis.
    Dong LP; Liu YM; Lu WJ; Tang KZ
    Eur Rev Med Pharmacol Sci; 2022 Sep; 26(17):6316-6327. PubMed ID: 36111933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.